FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
This article was originally published in The Tan Sheet
Executive Summary
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.
You may also be interested in...
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.
In Brief
Glaxo backs orlistat in light of ban request
In Brief
FDA finalizes OTC dosing guidance